Drug Names
ESMO Study Identifies Potential Predictive Biomarkers to ID TNBC Patients for Therapy De-Escalation
The study analyzed several biomarkers using Oncocyte's IO score, TNBCtype, and RNA sequencing, to identify response to neoadjuvant atezolizumab.
Early ESMO Data Show Interferon Signature's Ability to Guide Neoadjuvant Melanoma Immunotherapy
In the Phase I DOMINI trial, patients received combinations of BMS' Opdivo, Yervoy, and 4SC's domatinostat based on their tumors' interferon gamma gene expression.
Oncologists Bemoan 'Lousy' PD-L1 Biomarker in Light of New Adjuvant Tecentriq NSCLC Study Data
Premium
Updated results from IMpower010 showed NSCLC patients with PD-L1 expression in 1 to 49 percent of tumor cells derived less benefit from adjuvant Tecentriq than those with higher expression.
New data for KRAS inhibitors in colorectal cancer show promising results when combined with EGFR inhibitors.
Experts Consider Resistance, Combinations as Another HER2-Targeted Breast Cancer Drug Emerges
Byondis' trastuzumab duocarmazine improved progression-free survival compared to physicians' choice of treatment for metastatic HER2-positive breast cancer patients in a Phase III trial.